Evidence map›Paper›PMID 24748102›Full record

ArticlePloS one2014

Analysis of volatile compounds in exhaled breath condensate in patients with severe pulmonary arterial hypertension.

J K Mansoor, Edward S Schelegle, Cristina E Davis, William F Walby, Weixiang Zhao, Alexander A Aksenov, Alberto Pasamontes, Jennifer Figueroa, Roblee Allen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Metabolomics and Biomarker Discovery.Advances in experimental medicine and biology · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Pulmonary hypertension and chronic lung disease: where are we headed?European respiratory review : an official journal of the European Respiratory Society · 2019
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

J K MansoorDepartment of Physical Therapy, University of the Pacific, Stockton, California, United States of America.
Edward S SchelegleDepartment of Anatomy, Physiology and Cell Biology, University of California Davis, Davis, California, United States of America.
Cristina E DavisDepartment of Mechanical and Aerospace Engineering, University of California Davis, Davis, California, United States of America.
William F WalbyDepartment of Anatomy, Physiology and Cell Biology, University of California Davis, Davis, California, United States of America.
Weixiang ZhaoDepartment of Mechanical and Aerospace Engineering, University of California Davis, Davis, California, United States of America.
Alexander A AksenovDepartment of Mechanical and Aerospace Engineering, University of California Davis, Davis, California, United States of America.
Alberto PasamontesDepartment of Mechanical and Aerospace Engineering, University of California Davis, Davis, California, United States of America.
Jennifer FigueroaDepartment of Anatomy, Physiology and Cell Biology, University of California Davis, Davis, California, United States of America.
Roblee AllenDepartment of Medicine, University of California Davis Medical Center, Sacramento, California, United States of America.
University of California, Davis · USUniversity of California Davis Medical Center · USUniversity of the Pacific · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn important challenge to pulmonary arterial hypertension (PAH) diagnosis and treatment is early detection of occult pulmonary vascular pathology. Symptoms are frequently confused with other disease entities that lead to inappropriate interventions and allow for progression to advanced states of disease. There is a significant need to develop new markers for early disease detection and management of PAH. METHODOLGY AND

findingsExhaled breath condensate (EBC) samples were compared from 30 age-matched normal healthy individuals and 27 New York Heart Association functional class III and IV idiopathic pulmonary arterial hypertenion (IPAH) patients, a subgroup of PAH. Volatile organic compounds (VOC) in EBC samples were analyzed using gas chromatography/mass spectrometry (GC/MS). Individual peaks in GC profiles were identified in both groups and correlated with pulmonary hemodynamic and clinical endpoints in the IPAH group. Additionally, GC/MS data were analyzed using autoregression followed by partial least squares regression (AR/PLSR) analysis to discriminate between the IPAH and control groups. After correcting for medicaitons, there were 62 unique compounds in the control group, 32 unique compounds in the IPAH group, and 14 in-common compounds between groups. Peak-by-peak analysis of GC profiles of IPAH group EBC samples identified 6 compounds significantly correlated with pulmonary hemodynamic variables important in IPAH diagnosis. AR/PLSR analysis of GC/MS data resulted in a distinct and identifiable metabolic signature for IPAH patients.

conclusionsThese findings indicate the utility of EBC VOC analysis to discriminate between severe IPAH and a healthy population; additionally, we identified potential novel biomarkers that correlated with IPAH pulmonary hemodynamic variables that may be important in screening for less severe forms IPAH.

Indexed as

Breath TestsGas Chromatography-Mass SpectrometryHumansHypertension, PulmonaryLeast-Squares AnalysisVolatile Organic CompoundsVolatile Organic Compounds

Identifiers

PMID24748102
PMCPMC3991617
OpenAlexW2057469980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.